GRI Bio (GRI) AI Stock Analysis

• Market Cap: $1.39M
• Dividend Yield: N/A
• Average Volume (3M): 760.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.61
• Revenue Growth: N/A
• EPS Growth: 98.55%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -203.36
• Shares Outstanding: 727,358
• 10 Day Avg. Volume: 362,102
• 30 Day Avg. Volume: 760,071
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -3.84
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 1.33K
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $10.00
• Price Target Upside: 423.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

GRI Bio's stock is constrained by weak financial performance, with ongoing losses and significant cash burn. Technical indicators and valuation metrics further suggest caution, as the stock trades in a downtrend with negative profitability. The strong equity position provides some support, but overall, the stock is risky with limited appeal under current conditions.

Positive Factors

Drug Development

The company's initial main focus is on developing GRI-0621 for Idiopathic Pulmonary Fibrosis, a condition with a large market potential, affecting approximately 140,000 patients in the U.S.

Market Potential

GRI Bio is focused on developing treatments for diseases associated with dysregulated immune responses, which can potentially address a wide range of acute and chronic conditions.

Safety Profile

The reported data demonstrate GRI-0621 (4.5mg orally once daily) is safe and well-tolerated in the first 12 patients evaluated in the study.

Negative Factors

Clinical Trials Risk

Despite high risks associated with clinical trials, the potential market for the company's drugs is substantial, offering high rewards for the risks involved.

Development Timeline

GRI Bio expects key data from its Phase 2a trial for GRI-0621 in early 2025, which could significantly influence the stock if the results are positive.

GRI Bio Business Overview & Revenue Model

Company Description

GRI Bio (GRI) is a biotechnology company focused on developing innovative therapies to address unmet medical needs in the field of immunology. The company's core products and services revolve around its proprietary platform technology, which aims to modulate immune system responses to treat chronic inflammatory and fibrotic diseases. GRI Bio operates at the intersection of biotechnology and pharmaceuticals, striving to bring novel therapeutic solutions to market.

How the Company Makes Money

GRI Bio generates revenue through the development and commercialization of its proprietary therapies. The primary revenue streams include licensing agreements with pharmaceutical companies and potential milestone payments and royalties from successful drug candidates developed using their platform technology. Additionally, GRI Bio may engage in strategic partnerships and collaborations with other biotech firms to co-develop and market new therapies. The company's earnings are significantly influenced by its ability to advance drug candidates through clinical trials and secure regulatory approvals, as well as the establishment of lucrative partnerships with larger pharmaceutical entities.

GRI Bio Financial Statement Overview

Summary

GRI Bio shows improvement in revenue and equity position, yet struggles with profitability and cash flow. High operational costs and significant cash burn threaten financial stability despite a robust equity base.

Income Statement

GRI Bio's income statement shows some improvement in revenue from the previous year, with a TTM (Trailing-Twelve-Months) total revenue of $4.91 million, up from $0 in 2022. However, the company continues to face significant challenges in profitability, as indicated by negative net income and EBIT margins. The EBIT margin for the TTM is -103.5%, and the net profit margin is -167%, highlighting ongoing operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet reflects a stronger equity position, with stockholders' equity of $56.33 million as of the latest period, a recovery from previous negative equity figures. However, the debt-to-equity ratio is low at 0.002, indicating minimal leverage, which could be a positive factor in reducing financial risk. The equity ratio stands at 98.14%, showcasing a strong equity base relative to total assets, albeit with limited asset growth.

Cash Flow

GRI Bio's cash flow statement shows a negative operating cash flow and free cash flow in the TTM, with free cash flow at -$8.61 million. The operating cash flow to net income ratio is 1.05, suggesting the company is burning cash at a rate close to its net losses. Free cash flow growth remains negative, indicating ongoing challenges in generating cash from operations.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	21.77M	0.00	0.00	100.00K
	Gross Profit
-4.00K	21.71M	-206.00K	-73.00K	100.00K
	EBIT
-8.23M	-11.39M	-2.24M	-1.06M	-4.79M
	EBITDA
-8.20M	-10.90M	-2.51M	-9.21M	-4.71M
	Net Income Common Stockholders
-8.21M	-13.04M	-3.54M	-1.51M	-4.82M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
5.03M	1.81M	9.00K	90.00K	109.00K
	Total Assets
5.74M	2.96M	383.00K	218.00K	955.00K
	Total Debt
119.00K	14.00K	673.00K	3.61M	336.00K
	Net Debt
-4.91M	-1.79M	664.00K	3.52M	227.00K
	Total Liabilities
1.71M	2.70M	2.01M	4.94M	2.41M
	Stockholders Equity
4.03M	259.00K	-1.63M	-4.72M	-1.45M
Cash Flow		Free Cash Flow
-8.61M	-9.00M	-1.09M	-847.00K	-3.71M
	Operating Cash Flow
-8.61M	-9.14M	-1.08M	-847.00K	-3.71M
	Investing Cash Flow
0.00	-8.00K	-3.00K	-3.84M	-2.00K
	Financing Cash Flow
11.83M	10.95M	1.01M	600.00K	-4.00K

GRI Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.91
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRI, the sentiment is Negative. The current price of 1.91 is above the 20-day moving average (MA) of 1.67, below the 50-day MA of 4.01, and below the 200-day MA of 9.41, indicating a neutral trend. The MACD of -0.53 indicates Negative momentum. The RSI at 35.99 is Neutral, neither overbought nor oversold. The STOCH value of 41.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GRI.

GRI Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.23B	3.70	-41.86%	2.84%	16.58%	-0.16%
GRI	45 Neutral	$1.39M	―	-382.57%	―	―	98.55%
ONCO	33 Underperform	$3.08M	―	-233.77%	―	―	-97.16%
SLRX	30 Underperform	$1.56M	―	-164.02%	―	―	79.57%
PCSA	29 Underperform	$3.10M	―	-354.51%	―	―	56.26%
SCPX	23 Underperform	$557.45K	―	-174.06%	―	-10.75%	82.25%